Ascent Group LLC Has $4.33 Million Stock Position in Zoetis Inc. $ZTS

Key Points

• Ascent Group LLC increased its stake in Zoetis Inc. by 18.8% in Q1, holding 26,276 shares valued at $4.33 million.
• Several other institutional investors also raised their positions in Zoetis, with Sage Rhino Capital LLC growing its stake by 117.6%.
• Zoetis reported Q2 earnings of $1.76 per share, exceeding estimates and reflecting a 4.2% year-over-year revenue increase.

Ascent Group LLC increased its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 18.8% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 26,276 shares of the company's stock after purchasing an additional 4,158 shares during the period. Ascent Group LLC's holdings in Zoetis were worth $4,326,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Brighton Jones LLC lifted its position in shares of Zoetis by 180.4% during the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company's stock worth $754,000 after purchasing an additional 2,978 shares during the last quarter. Schonfeld Strategic Advisors LLC bought a new position in Zoetis during the fourth quarter worth $308,000. CoreCap Advisors LLC grew its position in Zoetis by 13.5% during the fourth quarter. CoreCap Advisors LLC now owns 1,050 shares of the company's stock worth $171,000 after buying an additional 125 shares in the last quarter. Gotham Asset Management LLC increased its stake in Zoetis by 100.8% during the fourth quarter. Gotham Asset Management LLC now owns 7,973 shares of the company's stock valued at $1,299,000 after acquiring an additional 4,002 shares during the period. Finally, Guardian Wealth Advisors LLC NC grew its holdings in shares of Zoetis by 23.8% during the 4th quarter. Guardian Wealth Advisors LLC NC now owns 1,281 shares of the company's stock worth $209,000 after purchasing an additional 246 shares in the last quarter. Institutional investors own 92.80% of the company's stock.

Zoetis Trading Down 1.5%

Shares of ZTS traded down $2.28 on Friday, reaching $148.33. 3,111,229 shares of the company's stock were exchanged, compared to its average volume of 2,278,915. The business has a 50 day moving average price of $152.32 and a two-hundred day moving average price of $157.31. Zoetis Inc. has a 12 month low of $139.70 and a 12 month high of $200.33. The stock has a market capitalization of $65.74 billion, a P/E ratio of 25.53, a price-to-earnings-growth ratio of 2.42 and a beta of 0.89. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping analysts' consensus estimates of $1.62 by $0.14. The firm had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business's quarterly revenue was up 4.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Analysts Set New Price Targets

ZTS has been the topic of several analyst reports. Leerink Partnrs lowered shares of Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Piper Sandler boosted their target price on Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a report on Monday, August 11th. Argus reissued a "buy" rating and issued a $190.00 price objective on shares of Zoetis in a research note on Tuesday. Leerink Partners cut shares of Zoetis from an "outperform" rating to a "market perform" rating and lowered their price objective for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Finally, Stifel Nicolaus lowered shares of Zoetis from a "buy" rating to a "hold" rating and reduced their target price for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Five analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, Zoetis currently has a consensus rating of "Moderate Buy" and a consensus target price of $200.88.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.